Trial Profile
Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Nov 2016
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia; Neutropenia; Non-Hodgkin's lymphoma
- Focus Expanded access; Therapeutic Use
- Sponsors Roche
- 27 May 2016 New trial record